Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...

Earnings Report 5.212 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.918 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.695 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

Adult star Lily Phillips says she knows she is 'part of the problem' after aiming to bed hundreds of men in extreme porn challenges. The 23-year-old has opened up about what took her from being a ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the ...

Both Kylie, 27, and Lily-Rose, 25, were in the French capital to watch the Chanel Haute Couture Spring-Summer 2025 show - but it's unsure if they actually came into contact with one another.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Bikini-clad Lily James looked gorgeous as she posed for a sizzling selfie by the beach. The Pam & Tommy star, 35, looked relaxed while on a swing - capturing herself in a stunning make-up free ...

In “Lilly,” writer-director Rachel Feldman follows the era-defining work of one such everyday woman: trailblazer Lilly Ledbetter, a pioneer from humble beginnings who took her employer ...

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.